Tumor necrosis factor activities and cancer therapy--a perspective - PubMed (original) (raw)
Review
Tumor necrosis factor activities and cancer therapy--a perspective
R S Sidhu et al. Pharmacol Ther. 1993 Jan.
Abstract
Tumor necrosis factor (TNF) is a multifunctional cytokine which has excited and fascinated numerous investigators and commercial entities due to its promise as a therapeutic agent against cancer and as a target for drugs treating septic shock. TNF is a protein having cytotoxic, cytostatic, immunomodulatory as well as several other activities and is also involved in septic shock. This review covers the structure of TNF and its receptors, various in vitro activities and in vivo activities based on studies in animal model systems. The role of TNF as an anticancer therapeutic agent, based on various phase I and phase II clinical studies, has also been considered. The review concludes with several considerations for increasing the therapeutic utility of TNF in terms of targeting, toxicity and half-life.
Similar articles
- Tumor necrosis factor as an antineoplastic agent: pitfalls and promises.
Mueller H. Mueller H. Cell Mol Life Sci. 1998 Dec;54(12):1291-8. doi: 10.1007/s000180050255. Cell Mol Life Sci. 1998. PMID: 9893706 Free PMC article. Review. - Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration.
Curnis F, Sacchi A, Corti A. Curnis F, et al. J Clin Invest. 2002 Aug;110(4):475-82. doi: 10.1172/JCI15223. J Clin Invest. 2002. PMID: 12189241 Free PMC article. - Strategies for improving the anti-neoplastic activity of TNF by tumor targeting.
Corti A. Corti A. Methods Mol Med. 2004;98:247-64. doi: 10.1385/1-59259-771-8:247. Methods Mol Med. 2004. PMID: 15064445 - Differences in the biological activity of TNF alpha and TNF beta correlate with their different abilities for binding to the target cells.
Kircheis R, Milleck J, Korobko VG, Shingarova LN, Schmidt HE. Kircheis R, et al. Eur Cytokine Netw. 1992 Jul-Aug;3(4):381-90. Eur Cytokine Netw. 1992. PMID: 1330049 - [TNF: antitumoral agent at the border lines of immunity and inflammation].
Branellec D, Chouaib S. Branellec D, et al. Pathol Biol (Paris). 1991 Mar;39(3):230-9. Pathol Biol (Paris). 1991. PMID: 1646993 Review. French.
Cited by
- Influence of cytokines on mdr1 expression in human colon carcinoma cell lines: increased cytotoxicity of MDR relevant drugs.
Walther W, Stein U. Walther W, et al. J Cancer Res Clin Oncol. 1994;120(8):471-8. doi: 10.1007/BF01191800. J Cancer Res Clin Oncol. 1994. PMID: 8207045 - TNF receptor 2 pathway: drug target for autoimmune diseases.
Faustman D, Davis M. Faustman D, et al. Nat Rev Drug Discov. 2010 Jun;9(6):482-93. doi: 10.1038/nrd3030. Epub 2010 May 21. Nat Rev Drug Discov. 2010. PMID: 20489699 Review. - Nanoparticle Delivery of Immunostimulatory Agents for Cancer Immunotherapy.
Zhuang J, Holay M, Park JH, Fang RH, Zhang J, Zhang L. Zhuang J, et al. Theranostics. 2019 Oct 15;9(25):7826-7848. doi: 10.7150/thno.37216. eCollection 2019. Theranostics. 2019. PMID: 31695803 Free PMC article. Review. - Modulation of mdr1 expression by cytokines in human colon carcinoma cells: an approach for reversal of multidrug resistance.
Stein U, Walther W, Shoemaker RH. Stein U, et al. Br J Cancer. 1996 Nov;74(9):1384-91. doi: 10.1038/bjc.1996.553. Br J Cancer. 1996. PMID: 8912533 Free PMC article. - The inflammatory cytokine tumor necrosis factor modulates the expression of Salmonella typhimurium effector proteins.
Ma J, Zhang YG, Xia Y, Sun J. Ma J, et al. J Inflamm (Lond). 2010 Aug 12;7:42. doi: 10.1186/1476-9255-7-42. J Inflamm (Lond). 2010. PMID: 20704730 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources